DOCSLIB.ORG

Us 2018 / 0271910 A1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Us 2018 / 0271910 A1 US 20180271910A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0271910 A1 Mata - Fink et al. (43 ) Pub . Date : Sep . 27 , 2018 ( 54 ) METHODS AND COMPOSITIONS FOR 2014 , provisional application No. 61/ 991, 319 , filed IMMUNOMODULATION on May 9 , 2014 , provisional application No . 61 / 973 , 764 , filed on Apr. 1 , 2014 , provisional application No. (71 ) Applicant : RUBIUS THERAPEUTICS , INC . , 61/ 973 ,763 , filed on Apr . 1 , 2014 . Cambridge , MA (US ) ( 30 ) Foreign Application Priority Data (72 ) Inventors : Jordi Mata - Fink , Somerville , MA (US ) ; John Round , Cambridge , MA Nov . 12 , 2014 (US ) .. .. .. PCT/ US2014 / 065304 (US ) ; Noubar B . Afeyan , Lexington , MA (US ) ; Avak Kahvejian , Arlington , Publication Classification MA (US ) (51 ) Int. CI. A61K 35 / 28 ( 2015 .01 ) ( 21 ) Appl. No. : 15 /911 , 924 C12N 5 / 078 ( 2010 . 01) A61K 48 / 00 ( 2006 .01 ) (22 ) Filed : Mar. 5 , 2018 C12N 5 /07 ( 2010 . 01 ) A61K 35 / 12 (2015 . 01) Related U . S . Application Data (52 ) U . S . CI. (63 ) Continuation of application No . 15 / 301, 046 , filed on CPC . .. .. .. A61K 35 / 28 ( 2013 .01 ) ; C12N 5 / 0644 Sep . 30 , 2016 , filed as application No . PCT/ US2015 / (2013 .01 ) ; C12N 5 / 0641 ( 2013 . 01 ) ; A61K 020614 on Mar . 13 , 2015 . 2035 / 124 (2013 . 01 ) ; C12N 5 / 06 ( 2013 . 01 ) ; (60 ) Provisional application No . 62/ 059 , 100 , filed on Oct . A61K 2035 / 122 (2013 .01 ) ; A61K 48 / 00 2 , 2014 , provisional application No . 62 /025 , 367 , filed ( 2013. 01 ) on Jul. 16 , 2014 , provisional application No. 62 / 006 , 828 , filed on Jun . 2 , 2014 , provisional application No . (57 ) ABSTRACT 62/ 006 ,825 , filed on Jun . 2 , 2014 , provisional appli Provided are cells containing exogenous antigen and uses cation No . 62 /006 ,829 , filed on Jun . 2 , 2014 , provi thereof . sional application No . 62 /006 , 832 , filed on Jun . 2 , Specification includes a Sequence Listing . Patent Application Publication Sep . 27 , 2018 Sheet 1 of 27 US 2018 /0271910 A1 WWWWWWWWWWWWWWW WWWWWW wwww " 85.8% 106105 ?????? w R3 Liposomes HighDose 104 100101102103104105106RL1-A Dewi mimibia migja tiiginimiminiwimming 0 59.6% 41414147444 105106 YA * *www Print pptate* ** . ww 1 ? 104 R3 100101102103104105106RL1-A Fig1 Liposomes LowDose * * * * * * * ???????????????????????????????????????????? 141414141414 TY 0 Hormone0 151 101 iiiiiiniiniiniiniiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii 0.06% ** 105106 5*104 R3 RL1-A NoLiposomes 104 100101102103104105106 R Nadada yoos 0 . ocaba K A - SSC Count FSC IgG SSC Count Patent Application Publication Sep . 27 , 2018 Sheet 2 of 27 US 2018 /0271910 A1 1 . E + 07 1 . E + 06 © 1C1. E ++ 0505 Wwwwwww . .. .. 1 . E + 04 - GPA Moleculespercell - | - - CKIT 1. E + 03 C . TR 1. E +02 - - Transgene 1 . E + 01 1 . E + 00 Expand Diff 1 Diff 2 Diff 3 Diff 3 Diff 3 Diff 3 D6 D5 D4 D2 D4 D6 D8 Fig 2 Patent Application Publication Sep . 27 , 2018 Sheet 3 of 27 US 2018 /0271910 A1 - Transgene + Transgene ? 6 R15 ? R16 ? R15 R16 ??????????????? None ???? .??? ????? ???????? ? ???? ?? ?? ?? ?????? ???? ?? ???? ???? 102?????????????? 101? R18 R18 ?????????? 10R17 Fig 3A " 100r : 101? - ????????? 102????? 103 ???? ???????? 104? 105??? 106 10 100 101 102 103 104 105 106 - Transgene + Transgene .??????????? ?????? R11 R16 06 R10 106??????????????? R15 ????????????????????????????? . ? ?????????????? 105 ????? ??????????????????? ? HAtag - 104 ? ???? GFP . ? . ?????????????????????????????????? ???? 103 ? ???????????? ??: ??? ???????????????????? 1?1 ?12 R13 R18 Fig 3B 1000 101 102 103 104 10529 106 10100 R1 101 102 103 104 105 106" - Transgene + Transgene ?????? ???? ?? ??????? ????? ?????? ????? ?????????? ???? ?? ?????? ?? ?? ?????? ????????? ??????????? ??? ???? ???? ???? ????? ????? ????? ???? ?? ????? ???? ????????? ??? ?????? ????? mmheid 107 2. 4 ??????????? 0. 384 107 14. 7 0 .502 106 ???????? ??????????????????????????? 106 ??????? ??????? 105 HAtag 104 mindennachmitmenBrillennanu None . ? ??????????????????????????????? 103??????? 102??????????????? 102 ???????????? mint 10 0 . 0815 Fig 3C 954102 104 105 246 Patent Application Publication Sep . 27 , 2018 Sheet 4 of 27 US 2018 /0271910 A1 ** per *** ing te* ** ip** *** *** * *** tiotuper tinish a * **** * nariri thispatsaites pusi in miütün ire in en orposteriore *rainst ination iniminti eneri*** *** * m s ** * nnunni s t ** erinterest witha prins contenitori propietarios*** * i ewswirere ma *** mimi ***** meserierenser sti cristianoposts rüya ris curiositats **** * * with *** * turtur proiectartikintische e a stiinarto Siria iniintertutur para inspireerimist isiewinningevindiripiretiapseterminira i e der stripes tortininin ** guminiusprisionero whicitari *** * iin portvere pintur Hopewaris iir inipristopitiriasmirtinaiheenvuurwoning meriroses verein ünün* ** * suu o rtunimirturnentitt i inuri onsistentesüstita de nhirittweitin itoru ** * vestirati www. sportprise mepiirirarúnir t ani naporiti count *** * ww.sout storiniuosecruric patyri mishprima pe rtisti co#wiaritiei o ** * upuesto indiscri ** scipientperistiwa w i rittiturremimoria contenureissarimsargirnissairement ir time totimu in * ** virturintipann printerper**** * proprietari piinamicizincturinn neriteprisimintiniuria pr inviisariatore turniir wie umowitymine irtirken r ipsarperritories i virtuturantnciper **** * * * s witteris ** **** * ** **Three* * ** * -spir ristiriitikut prinsipininisteriet harum tisunnustust the turnste wi rturere .** * *** urrieinamuhuri existier artmasi n u erapinyainapitet nturinointivirütünün r wi triptrait - b ** a pri sitioniniti som th r istatanimir *** * * * **Swimwerker samewerpworriemanager *** * * i * * i i ** **** * u interesiranim* propisima i ew*** * * per eraanture *** w er porement r uriitorii *** ** outrinti* * ** ons interestinni *** struc zümünüpürcuprinseinscrip Rips interesserterinowieniesustainaprip * ** M ustawiercie positii i propriisituntutunserenowniesakitangu ilmusprepositori pri Miercup o WAent tstume** * orri cine interviupti *** a w e reir pstiprina norisirisine e rtisinin t i ive wi ** * riemer * iorste singuripitouri suren **** * prisitüntetni piir ** ** ivedurid ** hipstúciqür **visited i sestistruct ** istupiti** ispiirterer ** i arent p vinsterut istitutid hituspininis e tutit pros ** * n *** ** Twitter T manier ** *** * * P i a ** intei * * * ner .sport sutrikipediasta ***arpinterv *** ***** * *** v winpoistü ** * **** * orrier rotestuestas*A** rentur uti Hümanistintuomittentárnourirent uru * **** * tut siepatrovatepapi t intri*-* * erover the p p tihara **** * * e n in innenine w r ituras e e emipaiempadroeiritinimo a * printerstitionersesthuispleiepiirrepressió in primis i ****Pitmietena ** * ai** r* * * ertiprintutor ithiriwiniert ürüritumiem pie*** * rviewswith esportistie +++ turimaw+ waitres*intentione * principiantisti igirtiti * *** tretinerenti ie n tisk *** * M wipe optimierereisimisation winter s timientos**** * s Utvietini *** **** p **** * *** ** erunturier *** * ** **** **** proprietárnychárterühmitur** tem i openimagine whos ** surv ***** * W e instipengisy sairastustürtistesinterioristiti istuututteriviimati * switcoinweisepintisinio meistrasipersone * nneritüitures inspireren* *** * www.mimpin r istup perintispinningarúrrin* * struir - * n riai primarne ristiras i r Universitarti** *** *** ** stenseitinternasionatoride pis o * ** 40 **** pupu *** tirati** * nwr *** meetupr** * einerweinirimairiews si rurit. unturiepeatsinrise cuprinsipinistiriitaimurai rev uviin i hupuhan eperisanje*sirritationesvities www . ** suprasowanie* priartinio propositioi restoran eiritür naria urini urp s writtenwir ürünuntiaritenutihistaminini nstoogmertimentodeint api pantai e ????????????????????????????????????????????????????????????????????????????????????????????????????? menimien ** *** * wintiguit richiestasiis artist *** * * * ithin**** tw i *** * reise www tartuntunin nitureto . swww t .simmäisiin tieto **** *** spieringspartiti** ** bomime üretimepigiworturientrasiiriintirtiirtung * ** ** rittenin these e weiteru*** * ww w strona sinuturintis ürinn turiuberritus uperrunguri depressioonisüstwww sevieriauswe i sienpirtti shpirtiswerk wertunanpew winstoptimi tipurposes Swi wigiteeriminerini ristrutur irtinti p minerite wip wr wire prvi Weimar www weiterinnertsgarrimiti ?????????????? w Sie sinistrore unui whirriperedpiripiruri w writer w S w Str with writer univerütürürrrrsarrer wünscr WWw w w w W Wüsturor Wei severwineries orrientieristiriitais trimitereve. wieran ** n * * emaith i i * ** posit ürii mortaisia **** * * * * ntation r r ithuê12viet .a ** *** * **** reneriranih *** * * * ** ospiterging participeid *** mi ** rio *** ** * * ** ry **** * * ** * * * ** siürünwistin WWW müürünün ermission istir *** institúprimeiros * ü poipartii oprie * * *** emptinestimationen ** eriserestrianüstr ihreiption i *** * * ** * operti. * n itupiai reikia a i interagiesquesimpsonstitutional p * ** * *** * ** * irirvintisi**** * * iai r ** ***** **** * * * ** * * * * * topish **** * * * * passer p pentincesce seper p ?iew+Give inverì *** * * stiation r internasionim in * ruurunesiminino resistent eritierinterio ** * i * ** aimerairesteswetenseries ****s yüresin ienie ier patinoarmeinsringi tertingurintis w represe prin intuitivnih s o etiminitortu rawitore sistemostititurtrouwrine s * pintar * ip*** a per t i #** * *** * * *** ** * hidheshirish retiremen t imü i ins e ionsP s t urinesürüpri puuttumisestavintsiatiseerimineintenciones esentareiras** interiores * with i serieurontinint win*ortioripostitust
Load more

Recommended publications
  • Current Therapies for Chronic Hepatitis C
    Southern Illinois University Edwardsville SPARK Pharmacy Faculty Research, Scholarship, and Creative Activity School of Pharmacy 1-2011 Current Therapies for Chronic Hepatitis C McKenzie C. Ferguson Southern Illinois University Edwardsville, [email protected] Follow this and additional works at: https://spark.siue.edu/pharmacy_fac Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Ferguson, McKenzie C., "Current Therapies for Chronic Hepatitis C" (2011). Pharmacy Faculty Research, Scholarship, and Creative Activity. 4. https://spark.siue.edu/pharmacy_fac/4 This Article is brought to you for free and open access by the School of Pharmacy at SPARK. It has been accepted for inclusion in Pharmacy Faculty Research, Scholarship, and Creative Activity by an authorized administrator of SPARK. For more information, please contact [email protected],[email protected]. Chronic Hepatitis C & Current Therapies 1 Review of Chronic Hepatitis C & Current Therapies Reviews of Therapeutics Pharmacotherapy McKenzie C. Ferguson, Pharm.D., BCPS From the School of Pharmacy, Southern Illinois University Edwardsville, Department of Pharmacy Practice, Edwardsville, Illinois. Address for reprint requests : Southern Illinois University Edwardsville School of Pharmacy 220 University Park Drive, Ste 1037 Edwardsville, IL 62026-2000 Email: [email protected] Keywords : hepatitis C, HCV, ribavirin, interferon, peginterferon alfa-2a, peginterferon alfa-2b, albinterferon, taribavirin, telaprevir, therapeutic efficacy, safety The author received no sources of support in the form of grants, equipment, or drugs. Chronic Hepatitis C & Current Therapies 2 ABSTRACT Hepatitis C virus affects more than 180 million people worldwide and as many as 4 million people in the United States. Given that most patients are asymptomatic until late in disease progression, diagnostic screening and evaluation of patients that display high-risk behaviors associated with acquisition of hepatitis C should be performed.
    [Show full text]
  • Harnessing the Power of Bacteria in Advancing Cancer Treatment
    International Journal of Molecular Sciences Review Microbes as Medicines: Harnessing the Power of Bacteria in Advancing Cancer Treatment Shruti S. Sawant, Suyash M. Patil, Vivek Gupta and Nitesh K. Kunda * Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Jamaica, NY 11439, USA; [email protected] (S.S.S.); [email protected] (S.M.P.); [email protected] (V.G.) * Correspondence: [email protected]; Tel.: +1-718-990-1632 Received: 20 September 2020; Accepted: 11 October 2020; Published: 14 October 2020 Abstract: Conventional anti-cancer therapy involves the use of chemical chemotherapeutics and radiation and are often non-specific in action. The development of drug resistance and the inability of the drug to penetrate the tumor cells has been a major pitfall in current treatment. This has led to the investigation of alternative anti-tumor therapeutics possessing greater specificity and efficacy. There is a significant interest in exploring the use of microbes as potential anti-cancer medicines. The inherent tropism of the bacteria for hypoxic tumor environment and its ability to be genetically engineered as a vector for gene and drug therapy has led to the development of bacteria as a potential weapon against cancer. In this review, we will introduce bacterial anti-cancer therapy with an emphasis on the various mechanisms involved in tumor targeting and tumor suppression. The bacteriotherapy approaches in conjunction with the conventional cancer therapy can be effective in designing novel cancer therapies. We focus on the current progress achieved in bacterial cancer therapies that show potential in advancing existing cancer treatment options and help attain positive clinical outcomes with minimal systemic side-effects.
    [Show full text]
  • Molecular Analysis of Candidate Probiotic Effector Molecules of Lactobacillus Plantarum
    Molecular analysis of candidate probiotic effector molecules of Lactobacillus plantarum Daniela Maria Remus Thesis committee Promoter Prof. dr. Michiel Kleerebezem Professor of Bacterial Metagenomics Wageningen University Co-promoter Dr. Peter A. Bron Senior Scientist, NIZO food research BV, Ede Other members Prof. dr. Tjakko Abee, Wageningen University Prof. dr. Pascal Hols, University of Lovain (Lovain la Neuve), Belgium Dr. Philippe Langella, National Institute of Agricultural Research (INRA), Paris, France Prof. dr. Roland J. Siezen, Radboud University, Nijmegen This research was conducted under the auspices of the Graduate School VLAG (Advanced studies in Food Technology, Agrobiotechnology, Nutrition and Health Sciences). Molecular analysis of candidate probiotic effector molecules of Lactobacillus plantarum Daniela Maria Remus Thesis submitted in fulfillment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. dr. M.J. Kropff, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Tuesday 09 October 2012 at 4 p.m. in the Aula. Daniela Maria Remus Molecular analysis of candidate probiotic effector molecules of Lactobacillus plantarum Ph.D. Thesis, Wageningen University, Wageningen, The Netherlands (2012) With references and summaries in English and Dutch. ISBN 978-94-6173-373-3 Summary Lactobacilli occupy diverse natural habitats, including dairy products and the mammalian gastrointestinal (GI) tract, and several Lactobacillus strains are marketed as probiotics that can interact with host cells in the GI tract by which they are proposed to beneficially influence the health status of their consumers. The discovery of probiotic effector molecules is instrumental to understand the exact modes of probiotic action, which is required for their controlled, safe, and purpose-directed application.
    [Show full text]
  • Plantaricin KW30
    The Molecular and Cellular Characterisation of the First Glycocin: Plantaricin KW30 Judith Stepper 2009 The Molecular and Cellular Characterisation of the First Glycocin: Plantaricin KW30 A thesis presented in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biochemistry at Massey University, Palmerston North, New Zealand Judith Stepper 2009 “What we know is a drop. What we don’t know is an ocean.” Isaac Newton (1643 – 1727) ABSTRACT Bacteriocins, typically secreted by Gram-positive and -negative bacteria, are ribosomally- synthesised antimicrobial peptides which inhibit the growth of competing bacteria. We have purified a 43 amino acid bacteriocin, plantaricin KW30 (PlnKW30) produced by Lactobacillus plantarum KW30, that has little amino acid sequence similarity to any other characterised bacteriocin. The gene encoding plnKW30 is in a cluster with the genes required for maturation and export of, and immunity to, the bacteriocin. This arrangement of genes is similar to the genomic context of bacteriocin genes in other lactic acid bacteria. The plnKW30 gene cluster comprises six genes encoding a glycosyltransferase, a proteolytic ABC-transporter, two putative thioredoxins, a response regulator and PlnKW30 itself. PlnKW30 was found to possess two unusual post-translational modifications: an O-glycosylated serine and an unprecedented S-glycosylation of the C-terminal cysteine. The modified serine is located on an eight residue loop that is tethered by a disulfide bridge. Both modifications have been identified as N-acetylglucosamines (GlcNAc), making PlnKW30 the first described class IV bacteriocin. A post-translational modification with S-linked GlcNAc is unprecedented in bacteriocins as well as in all genera.
    [Show full text]
  • The Bacteriostatic Diglycocylated Bacteriocin Glycocin F Targets A
    Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author. The Bacteriostatic Diglycosylated Bacteriocin Glycocin F Targets a Sugar-Specific Transporter A thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Biochemistry at Massey University, Manawatu New Zealand Kelvin Ross Drower 2014 Dedicated to Nana and Pop Abstract The increasing prevalence of antibiotic-resistance bacteria is threatening to end the antibiotic era established following Alexander Fleming's discovery of penicillin in 1928. Over-prescription and misuse of broad-spectrum antibiotics has hastened the development and spread of antibiotic resistance. This, combined with a lack of research and development (R&D) of new antibiotics by major pharmaceutical companies, may lead to a widespread recurrence of 'incurable' bacterial diseases. However while commercial R&D of antibiotics has waned, much research has been carried out to characterise bacteriocins, ribosomally-synthesised antimicrobial polypeptides thought to be produced by virtually all prokaryotes. Although hundreds of bacteriocins have been identified and characterised, only a handful of their cognate receptors on susceptible cells have been identified. Glycocin F is a bacteriostatic diglycosylated 43-amino acid bacteriocin produced by the Gram-positive bacterium Lactobacillus plantarum KW30 that inhibits the growth of a broad range of bacteria. The mechanism of action of glycocin F is unknown, however evidence suggested that glycocin F binds to cells via a N-acetylglucosamine (GlcNAc) specific phosphoenolpyruvate:carbohydrate-phosphotransferase system (PTS) transporter, as had been shown for lactococcin A, lactococcin B and microcin E492 that target a mannose specific PTS transporter.
    [Show full text]
  • UC Berkeley Electronic Theses and Dissertations
    UC Berkeley UC Berkeley Electronic Theses and Dissertations Title Interactions of Microbes in Communities Permalink https://escholarship.org/uc/item/2hg5h7k6 Author Sczesnak, Andrew Publication Date 2018 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Interactions of Microbes in Communities By Andrew Sczesnak A dissertation submitted in partial satisfaction of the requirements for the degree of Joint Doctor of Philosophy with University of California, San Francisco in Bioengineering in the Graduate Division of the University of California, Berkeley Committee in charge: Professor Adam P. Arkin, Chair Professor Matthew Traxler Professor Michael Fischbach Fall 2018 Abstract Interactions of Microbes in Communities By Andrew Sczesnak Joint Doctor of Philosophy with University of California, San Francisco in Bioengineering University of California, Berkeley Professor Adam P. Arkin, Chair Groups of microorganisms sharing an environment (microbial communities) are ubiquitous in nature. Microbial communities provide essential ecosystem services to other life on Earth by e.g., participating in global biogeochemical processes or interacting with a host’s immune system. Such microbes compete for scarce resources, modify an environment for their own purposes, actively war, and occasionally cooperate. Though numerous studies have surveyed the diversity of microbial life in different environments, few have determined the ways in which members of microbial communities interact with one another. Understanding the ways and means by which microbes interact is essential if we are to understand how microbial communities form, persist, and change over time. Knowledge of these processes will allow us to rationally design microbial communities to perform useful functions and predict how our actions might shift the balance of microbes in a community, and thus affect its function.
    [Show full text]
  • THE CONCISE GUIDE to PHARMACOLOGY 2017/18 Alexander, Stephen P
    University of Dundee THE CONCISE GUIDE TO PHARMACOLOGY 2017/18 Alexander, Stephen P. H.; Fabbro, Doriano; Kelly, Eamonn; Marrion, Neil V.; Peters, John A.; Faccenda, Elena Published in: British Journal of Pharmacology DOI: 10.1111/bph.13876 Publication date: 2017 Licence: CC BY Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Alexander, S. P. H., Fabbro, D., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., & CGTP Collaborators (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Catalytic receptors. British Journal of Pharmacology, 174 (Suppl. 1), S225-S271. https://doi.org/10.1111/bph.13876 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 23. Sep. 2021 S.P.H.
    [Show full text]
  • US 2017/0020926 A1 Mata-Fink Et Al
    US 20170020926A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0020926 A1 Mata-Fink et al. (43) Pub. Date: Jan. 26, 2017 (54) METHODS AND COMPOSITIONS FOR 62/006,825, filed on Jun. 2, 2014, provisional appli MMUNOMODULATION cation No. 62/006,829, filed on Jun. 2, 2014, provi sional application No. 62/006,832, filed on Jun. 2, (71) Applicant: RUBIUS THERAPEUTICS, INC., 2014, provisional application No. 61/991.319, filed Cambridge, MA (US) on May 9, 2014, provisional application No. 61/973, 764, filed on Apr. 1, 2014, provisional application No. (72) Inventors: Jordi Mata-Fink, Somerville, MA 61/973,763, filed on Apr. 1, 2014. (US); John Round, Cambridge, MA (US); Noubar B. Afeyan, Lexington, (30) Foreign Application Priority Data MA (US); Avak Kahvejian, Arlington, MA (US) Nov. 12, 2014 (US) ................. PCT/US2O14/0653O4 (21) Appl. No.: 15/301,046 Publication Classification (22) PCT Fed: Mar. 13, 2015 (51) Int. Cl. A6II 35/28 (2006.01) (86) PCT No.: PCT/US2O15/02O614 CI2N 5/078 (2006.01) (52) U.S. Cl. S 371 (c)(1), CPC ............. A61K 35/28 (2013.01); C12N5/0641 (2) Date: Sep. 30, 2016 (2013.01): CI2N 5/0644 (2013.01); A61 K Related U.S. Application Data 2035/122 (2013.01) (60) Provisional application No. 62/059,100, filed on Oct. (57) ABSTRACT 2, 2014, provisional application No. 62/025,367, filed on Jul. 16, 2014, provisional application No. 62/006, Provided are cells containing exogenous antigen and uses 828, filed on Jun. 2, 2014, provisional application No.
    [Show full text]
  • Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation
    Review Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation Leonor S. Castro 1,†, Guilherme S. Lobo 1,†, Patrícia Pereira 2 , Mara G. Freire 1 ,Márcia C. Neves 1,* and Augusto Q. Pedro 1,* 1 CICECO–Aveiro Institute of Materials, Chemistry Department, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal; [email protected] (L.S.C.); [email protected] (G.S.L.); [email protected] (M.G.F.) 2 Centre for Mechanical Engineering, Materials and Processes, Department of Chemical Engineering, University of Coimbra, Rua Sílvio Lima-Polo II, 3030-790 Coimbra, Portugal; [email protected] * Correspondence: [email protected] (M.C.N.); [email protected] (A.Q.P.) † These authors contributed equally to this work. Abstract: The advent of biopharmaceuticals in modern medicine brought enormous benefits to the treatment of numerous human diseases and improved the well-being of many people worldwide. First introduced in the market in the early 1980s, the number of approved biopharmaceutical products has been steadily increasing, with therapeutic proteins, antibodies, and their derivatives accounting for most of the generated revenues. The success of pharmaceutical biotechnology is closely linked with remarkable developments in DNA recombinant technology, which has enabled the production of proteins with high specificity. Among promising biopharmaceuticals are interferons, first described by Isaacs and Lindenmann in 1957 and approved for clinical use in humans nearly thirty years later. Interferons are secreted autocrine and paracrine proteins, which by regulating several biochemical Citation: Castro, L.S.; Lobo, G.S.; pathways have a spectrum of clinical effectiveness against viral infections, malignant diseases, Pereira, P.; Freire, M.G.; Neves, M.C.; and multiple sclerosis.
    [Show full text]
  • Quantum of Effectiveness Evidence in FDA's Approval of Orphan Drugs
    Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs Cataloguing FDA’s Flexibility in Regulating Therapies for Persons with Rare Disorders by Frank J. Sasinowski, M.S., M.P.H., J.D.1 Chairman of the Board National Organization for Rare Disorders One of the key underlying issues facing the development of effective for their intended uses. all drugs, and particularly orphan drugs, is what kind of evi- dence the Food and Drug Administration (FDA) requires for FDA has for many decades acknowledged that there is a need approval. The Federal Food, Drug, and Cosmetic [FD&C] Act IRUÁH[LELOLW\LQDSSO\LQJLWVVWDQGDUGIRUDSSURYDO)RUH[- provides that for FDA to grant approval for a new drug, there ample, one of FDA’s regulations states that: “FDA will ap- must be “substantial evidence” of effectiveness derived from prove an application after it determines that the drug meets the “adequate and well-controlled investigations.” This language, statutory standards for safety and effectiveness… While the which dates from 1962, provides leeway for FDA medical re- statutory standards apply to all drugs, the many kinds of drugs viewers to make judgments as to what constitutes “substantial that are subject to the statutory standards and the wide range HYLGHQFHµRIDGUXJ·VHIIHFWLYHQHVVWKDWLVRILWVEHQHÀWWR RIXVHVIRUWKRVHGUXJVGHPDQGÁH[LELOLW\LQDSSO\LQJWKHVWDQ- patients. GDUGV7KXV)'$LVUHTXLUHGWRH[HUFLVHLWVVFLHQWLÀFMXGJPHQW to determine the kind and quantity of data and information an 7KHVROHODZWKDWDSSOLHVVSHFLÀFDOO\WRRUSKDQGUXJVWKH2U- applicant is required to provide for a particular drug to meet SKDQ'UXJ$FWRISURYLGHGÀQDQFLDOLQFHQWLYHVIRUGUXJ the statutory standards.” 21 C.F.R. § 314.105(c). FRPSDQLHVWRGHYHORSRUSKDQGUXJVZKLFKLVOHJDOO\GHÀQHG as products that treat diseases that affect 200,000 or fewer )'$SXEOLFO\KDVH[SUHVVHGVHQVLWLYLW\WRDSSO\LQJWKLVÁH[- patients in the U.S.
    [Show full text]
  • NMMC West Point CDM.Xlsx
    Facility Description Price CC SWING BED RUGS CODE CC PRIVATE 1ST WEST 861 CC PRIVATE OBSTETRICS 861 CC BAKRI BALLOON FOR PP HEMR 661 CC BAKRI BALLOON FOR PP HEMR 661 CC RPR CMPX LID/N/L 2.6‐7.5 1914 CC RPR CMPX LID/N/ E/A 5CM/< 1053 CC RPR CMPX LID/N/L 2.6‐7.5 1914 CC RPR CMPX LID/N/ E/A 5CM/< 1053 CC PRIVATE ECU 494 CC IV THRPY FIRST HR DX 691 CC IV THRPY EA/ADD HR DX 190 CC IV THRPY ADD/SEQ TO 1 HR 205 CC IV THRPY CONCURRENT 122 CC IV THRPY FIRST HR HYDRTN 690 CC IV THRPY EA/ADD HR HYDRTN 134 CC INJ IV EA ADD DIFF MED 269 CC RECOVERY PER HOUR 280 CC MINOR PROCEDURE 1627 CC ARTERIAL LINE PLACEMENT 463 CC INJ EPIDURAL BLOOD PATCH 2850 CC INJ IV PUSH INITIAL 692 CC ADDITIONAL CPT CODE CC MED ICU ROOM CHARGE 1872 CC NURSERY 1200 CC CIRC TRAY 91 CC INIT HOSP CARE LV 1 P/DAY 205 CC INIT HOSP CARE LV 2 P/DAY 279 CC INIT HOSP CARE LV 3 P/DAY 412 CC SUBS HOSP CARE LV 1 P/DAY 81 CC SUBS HOSP CARE LV 2 P/DAY 147 CC SUBS HOSP CARE LV 3 P/DAY 212 CC HOSP DAY MGMT 30 MNT OR < 147 CC HOSP DAY MGMT > 30 MNTS 214 CC OBS CARE D/C DAY MGMT 155 CC INITL OBS CARE LV 1 P/DAY 197 CC INITL OBS CARE LV 2 P/DAY 239 CC INITL OBS CARE LV 3 P/DAY 362 CC SUBS OBS CARE LV 1 P/DAY 88 CC SUBS OBS CARE LV 2 P/DAY 145 CC SUBS OBS CARE LV 3 P/DAY 236 CC SNF D/C DAY MGMT 30 OR < 240 CC SNF D/C DAY MGMT >30 318 CC PERC REPLAC J TUBE W/O FL 1948 CC INITIAL NF CARE LEVEL 1 204 CC INITIAL NF CARE LEVEL 2 290 CC INITIAL NF CARE LEVEL 3 368 CC SUBSQENT NF CARE LEVEL 197 CC SUBSQENT NF CARE LEVEL 2 151 CC SUBSQENT NF CARE LEVEL 3 198 CC SUBSQENT NF CARE LEVEL 4 295 CC OBS OR I/P
    [Show full text]
  • Monitoring and Mathematical Modeling of in Vitro Human Megakaryocyte Expansion and Maturation Dynamics
    YOUNES LEYSI-DERILOU MONITORING AND MATHEMATICAL MODELING OF IN VITRO HUMAN MEGAKARYOCYTE EXPANSION AND MATURATION DYNAMICS Thèse présentée à la Faculté des études supérieures de l’Université Laval dans le cadre du programme de doctorat en génie chimique pour l’obtention du grade de Philosophiae doctor (Ph.D.) DEPARTMENT DE GÉNIE CHIMIQUE FACULTÉ DE SCIENCES ET GÉNIE UNIVERSITÉ LAVAL QUÉBEC 2011 © Younes Leysi-Derilou, 2011 ii Résumé La mégakaryopoïèse est un processus complexe, qui prend naissance à partir des cellules souches hématopoïétiques (HSC). Ces dernières se différencient par étapes successives en mégakaryocytes (MKs) qui, suite à leur maturation, libèrent les plaquettes. Afin de modéliser le sort des HSCs lors de la mégakaryopoïèse en culture, un nouveau modèle mathématique a été développé, basé sur un programme de différenciation tridimensionnelle (3-D) où chaque sous-population est représentée par un compartiment. Dans le but d’évaluer la prolifération, la différenciation des MKs immatures puis matures, la cinétique de mort cellulaire ainsi que le nombre de plaquettes produites, à partir des cellules de sang de cordon (CB) ombilical enrichies en CD34+, un ensemble d'équations différentielles a été déployé. Les cellules CD34+ ont été placées en culture dans un milieu optimisé pour la différenciation mégakaryocytaire. Les paramètres cinétiques ont été estimés pour deux températures d'incubation (37°C versus 39°C). Les résultats des régressions ont été validés par l'évaluation de l'estimabilité des paramètres, en utilisant des analyses de sensibilité locale et globale, puis la détermination d'un intervalle de confiance. Ceux-ci ont été comparés par le biais de tests statistiques et d’analyses en composante principale (ACP).
    [Show full text]